Tau PET Imaging for Primary Progressive Aphasia
Trial Summary
What is the purpose of this trial?
This trial aims to see if a PET scan with a special tracer can map harmful protein build-up in the brains of people with language problems due to Primary Progressive Aphasia.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the drug 18F-AV-1451 (Flortaucipir, Tauvid, 18F-T807) for primary progressive aphasia?
The drug 18F-AV-1451, also known as Flortaucipir, is primarily used to detect tau protein build-up in the brain, which is common in Alzheimer's disease. While it shows strong links to tau burden in Alzheimer's patients, its effectiveness in detecting tau in non-Alzheimer's conditions like primary progressive aphasia is limited, although some regional associations have been observed.12345
Is 18F-flortaucipir (also known as 18F-AV-1451, Flortaucipir, Tauvid, 18F-T807) safe for use in humans?
18F-flortaucipir has been used in various studies for imaging tau protein in the brain, particularly in Alzheimer's disease and other cognitive impairments. While these studies focus on its effectiveness in detecting tau, they do not report significant safety concerns, suggesting it is generally safe for use in humans.13567
How does the drug 18F-flortaucipir differ from other treatments for primary progressive aphasia?
18F-flortaucipir is unique because it is a PET imaging agent that helps visualize tau protein deposits in the brain, which is not a standard treatment but a diagnostic tool to understand the disease better. Unlike other treatments that may focus on symptom management, this drug provides insights into the underlying pathology of primary progressive aphasia by highlighting tau accumulation patterns.13468
Research Team
Emily Rogalski, Ph.D.
Principal Investigator
University of Chicago
Eligibility Criteria
This trial is for individuals with Primary Progressive Aphasia and other related dementias. Participants must not be pregnant, breastfeeding, or undergoing clinical radiation treatments.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Imaging
Participants receive an injection of 10 Mci of AV-1451 and undergo PET scanning for brain imaging
Follow-up
Participants are monitored for tau deposition levels using standardized uptake value ratio (SUVR) in cortical and medial temporal regions
Treatment Details
Interventions
- 18F-AV-1451
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Chicago
Lead Sponsor
Northwestern University
Lead Sponsor
National Institute on Aging (NIA)
Collaborator